Skip to content
All articles

Multicenter phase 1b trial of neoadjuvant nivolumab plus ipilimumab for surgically resectable hepatocellular carcinoma

Prof. David Pinato
Prof. David Pinato

The phase 1b PRIME-HCC study at three UK centers (Hammersmith Hospital and St Bartholomew’s Hospital, both in London, and Royal Surrey Hospital in Guildford) evaluated the combination of nivolumab and ipilimumab as neoadjuvant therapy for surgically resectable hepatocellular carcinoma (HCC) in adult patients with Child-Pugh A liver function and ECOG performance status 0-1. Patients received nivolumab 3 mg/kg on days 1 and 22 of the first and second cycle and ipilumab 1 mg/kg on day 1 of the first cycle only before liver resection. The primary endpoint was safety. A total of 33 patients were enrolled (24% female; median age 68 years; IQR 63-73). The median follow-up was 25.7 months (95% CI 21.2-30.1). Treatment-related adverse events occurred in 76% (grade 3 in 9%), and serious adverse events in 9%; no grade 4 or 5 events or treatment-related deaths occurred. Ninety-one percent of patients underwent surgery, including 6% who had immune checkpoint inhibitor-related surgery delays. Objective response was noted in eight patients (25%; 95% CI 13-52; one complete response), with 31 patients (97%; 84-100) achieving disease control. Absence of ctDNA after surgery was associated with improved recurrence-free survival (p=0.049), as was at least 50% ctDNA reduction (p=0.039). Patients with objective responses showed expansion of peripheral PD-1-positive, Ki-67-positive, CD8-positive T cells. Patients whose disease did not respond to treatment exhibited enrichment of terminally exhausted CD8-positive T cells and regulatory T cells. The authors conclude that neoadjuvant nivolumab plus ipilimumab is feasible in early-stage resectable HCC; later-phase randomized trials are needed to confirm the efficacy of this strategy. Longitudinal ctDNA monitoring could support detection of minimal residual disease.

Original publicationthelancet.com
Read the publication